0001209191-14-029095.txt : 20140424 0001209191-14-029095.hdr.sgml : 20140424 20140424172401 ACCESSION NUMBER: 0001209191-14-029095 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140422 FILED AS OF DATE: 20140424 DATE AS OF CHANGE: 20140424 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KANIA EDWIN M JR CENTRAL INDEX KEY: 0001255927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 14782517 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-04-22 0 0001280600 ACCELERON PHARMA INC XLRN 0001255927 KANIA EDWIN M JR C/O FLAGSHIP VENTURES, 1 MEMORIAL DRIVE CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2014-04-22 4 S 0 114746 35.89 D 2031974 I See Footnote Common Stock 2014-04-22 4 S 0 6936 35.89 D 122823 I See Footnote Common Stock 2014-04-23 4 S 0 22349 33.81 D 2009625 I See Footnote Common Stock 2014-04-23 4 S 0 1351 33.81 D 121472 I See Footnote Common Stock 2014-04-24 4 S 0 805905 31.45 D 1203720 I See Footnote Common Stock 2014-04-24 4 S 0 48713 31.45 D 72759 I See Footnote Common Stock 4867 D The price reported in Column 4 is a weighted average price. These shares were disposed of by Applied Genomic Technology Capital Fund, L.P. ("AGTC Fund") and AGTC Advisors Fund, L.P. ("AGTC Advisors") in multiple transactions on the Transaction Date at prices ranging from $35.00 to $36.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, and/or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), and (5) to this Form 4. All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by AGTC Fund and AGTC Advisors on December 16, 2013. Represents shares held by AGTC Fund. NewcoGen Group, Inc. ("NewcoGen Inc.") is the general partner of AGTC Partners, L.P., which is the general partner of AGTC Fund. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. Noubar B. Afeyan, Ph.D. and Mr. Kania are the directors of Flagship Venture Management, Inc. and, as such, have shared voting and dispositive power over all shares held by AGTC Fund. Each of Mr. Kania and Dr. Afeyan disclaim beneficial ownership over the shares held by AGTC Fund except to the extent of his pecuniary interest therein. Represents shares held by AGTC Advisors. NewcoGen Group, Inc. ("NewcoGen Inc.") is the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. Noubar B. Afeyan, Ph.D. and Mr. Kania are the directors of Flagship Venture Management, Inc. and, as such, have shared voting and dispositive power over all shares held by AGTC Advisors. Each of Mr. Kania and Dr. Afeyan disclaim beneficial ownership over the shares held by AGTC Advisors except to the extent of his pecuniary interest therein.. The price reported in Column 4 is a weighted average price. These shares were disposed of by AGTC Fund and AGTC Advisors in multiple transactions on the Transaction Date at prices ranging from $33.15 to $35.26, inclusive. The price reported in Column 4 is a weighted average price. These shares were disposed of by AGTC Fund and AGTC Advisors in multiple transactions on the Transaction Date at prices ranging from $30.50 to $33.52, inclusive. /s/ Edwin M. Kania, Jr. 2014-04-24